We have read with interest the comments made by Chang and Gau[1] concerning the complicated interaction between colchicine and COVID-19, and potential biases due to the severity of gout and the comorbidity status of neurological diseases. However, since our data were sourced from electronic medical records, information on the indication for colchicine treatment, gout status and severity, and uric acid levels was not available. We agree with Chang and Gau on the interest attaching to the possible influence of gout severity on COVID-19 severity and progression.